Tallysomycin, a new antitumor antibiotic complex related to bleomycin. V. Production, characterization and antitumor activity of tallysomycin S10b, a new biosynthetic tallysomycin derivative.
Tallysomycin S10b is a biosynthetic derivative of tallysomycin B obtained by precursor amine-feeding fermentation. Tallysomycin S10b contains 1,4-diaminobutane as the terminal amine moiety in place of spermidine of tallysomycin B, and its assigned structure was verified by carbon-13 NMR spectrum. The antitumor activity of tallysomycin S10b was comparable to that of tallysomycin A against sarcoma 180 but less active than the latter against leukemia P388. Tallysomycin S10b was less toxic than tallysomycin A in terms of acute and subacute LD50 values. The nephrotoxic potential of tallysomycin S10b in rats was less than that of tallysomycin A.
D000192:Actinomycetales / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000032:analysis / Q000096:biosynthesis* / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects; D001761:Bleomycin / Q000032:analysis / Q000096:biosynthesis* / Q000494:pharmacology / Q000627:therapeutic use / Q000031:analogs & derivatives; D055598:Chemical Phenomena; D002621:Chemistry; D005285:Fermentation; D005658:Fungi / Q000187:drug effects; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin; C016126:talisomycin